SLC2A1 and non-small cell lung carcinoma: In conclusion, we demonstrated in this study that GLUT1-mediated glucose metabolism contributes to gefitinib resistance of NSCLC cells and that glucose uptake associated with GLUT1 expression remains active after gefitinib treatment in gefitinib-resistant NSCLC cells.